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The colonic microbiota play a key role in human 
gastrointestinal tract physiology include 
maintaining homeostasis of the large bowel and 
modulating the host immune response. Lactic acid 
bacteria (LAB) especially Lactobacillus and 
Bifidobacterium are the main part of gut 
microbiota, which are considered as health 
beneficial probiotic bacteria with valuable effects 
in humans [1, 2]. 
Probiotic bacteria are currently used in 
industrial food production and therapeutically 
procedures [3]. The lactic acid produced by 
probiotic bacteria in the fermentation process 
causes decrease pH to inhibit the growth of 
putrefactive and pathogenic bacteria. Besides, 
LAB could have improvement effects on the 
nutritional value of fermented products through 
increase the production of the main food 
components such as vitamins, essential minerals, 
and amino acids [4]. Probiotics have been shown 
to be effective in preventing and treating different 
disorders such as atopic dermatitis, urinary tract- 
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infections, colorectal cancer, and rheumatoid 
arthritis [5]. Competition with disease-causing 
microbes, producing antimicrobial peptides 
(AMPs), modulate the microenvironment and 
regulate the host immune system makes probiotics 
a very interesting field for infectious disease 
research [6]. 
Since December 2019, coronavirus disease 2019 
(COVID-19) caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) affected 
many people globally, and finding new treatment 
strategies is crucial [7]. To date, there is not strong 
practical evidence that showed the use of 
probiotics has promising effects in patients with 
COVID-19. However, previous studies suggested 
that the use of probiotics may reduce or prevent 
some of the major complications of COVID-19. 
The most significant cases are reducing antibiotic 
associated-diarrhea and ventilator-associated 
pneumonia, and prevention of acute respiratory 
distress syndrome (ARDS) and upper respiratory 
tract infections (RTIs) [8, 9]. Regarding the 
prevention of RTIs, probiotics maybe not directly 
affect SARS-CoV-2 but can be efficient for 
reducing the risk of co-infections [9]. 
Previous indirect evidence gives us hope that 
probiotics research might eventually deliver 
therapeutic options for fighting against COVID-
19, but until reaching that goal further in vitro and   
in vivo researches will be highly needed. 
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